Effects of vasoactive intestinal polypeptide infusions on renal function in patients with liver disease.
1. The effect of intravenous vasoactive intestinal peptide (VIP, 6 pmol/kg per min) on renal function in six patients with cirrhosis of the liver was examined. 2. VIP caused generalized vasodilation and increased plasma renin activity, but diminished the glomerular filtration rate by about one third. 3. The excretion of water, sodium, potassium and calcium also fell significantly. 4. These results differ from our findings in normal man in whom VIP diminished water and electrolyte secretion largely by increasing tubular reabsorption. 5. It is concluded that the elevated VIP levels present in patients with severe liver disease may affect renal function, but that the presence of liver disease may affect renal responses to VIP.
Calam
J
J
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
Unwin
R J
RJ
Dorudi
S
S
Taylor
C
C
Springer
C J
CJ
Peart
W S
WS
D001772:Blood Cell Count; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007677:Kidney Function Tests; D008104:Liver Cirrhosis, Alcoholic / Q000503:physiopathology; D008107:Liver Diseases / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology*
D014660:Vasoactive Intestinal Peptide